Search

UT Southwestern Medical Center has joined more than a dozen leading medical centers and Microsoft to form the Trustworthy & Responsible AI Network (TRAIN), a national group designed to set standards and safely explore applications of artificial intelligence (AI) in health care.

Children who undergo expansive genetic sequencing may not be getting the thorough DNA analysis their parents were expecting, say experts at UT Southwestern Medical Center.

Children who had preexisting health problems or who lived in the Southern United States had a higher risk for severe health outcomes from acute COVID-19 infections, according to researchers at UT Southwestern Medical Center.

Using machine learning tools to analyze hundreds of proteins, UT Southwestern researchers have identified a group of biomarkers in blood that could lead to an earlier diagnosis of children with autism spectrum disorder (ASD) and, in turn, more effective therapies sooner.

Blocking a molecule that draws sensory nerves into musculoskeletal injuries prevents heterotopic ossification (HO), a process in which bone abnormally grows in soft tissue during healing

Catherine Spong, M.D., Chair and Professor of Obstetrics and Gynecology at UT Southwestern Medical Center, has been elected to the National Academy of Medicine (NAM) in recognition of her significant impact on the field of maternal-fetal medicine, her leadership in women’s health research, and her

A new initiative funded by The University of Texas System and the state of Texas seeks to improve care for trauma patients.

Reuben Arasaratnam, M.D., M.P.H., Assistant Professor of Internal Medicine at UT Southwestern, has been named one of 11 2022 Scholars in Diagnostic Excellence by the National Academy of Medicine (NAM).

Interstitial pneumonia with autoimmune features (IPAF) is a disease with many possible causes and no standard of care, making it particularly difficult to treat. While immunosuppressant drugs are primarily prescribed, they don’t work for all patients.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).